摘要
目的探讨干扰素与恩替卡韦联合治疗慢性乙型病毒肝炎初治患者的临床效果。方法选取2014年6月至2016年1月我院慢性乙型病毒肝炎初次治疗患者76例为研究对象,经随机数字表法分为观察组与对照组,各38例。对照组给予干扰素治疗,观察组在对照组基础上加用恩替卡韦治疗,观察两组患者病毒学、血清学指标,肝功能指标及不良反应发生情况。结果治疗8周后,两组HBV DNA转阴率、HBeAg转阴率及HBeAg血清转换率比较,差异无统计学意义(P>0.05);治疗24周后,观察组患者上述指标显著高于对照组,差异有统计学意义(P<0.05);治疗48周后,观察组患者上述指标显著高于对照组,差异有统计学意义(P<0.05)。治疗前两组患者血清AST、ALT水平比较,无显著差异(P>0.05);治疗48周后,观察组患者血清AST、ALT水平明显低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论慢性乙型病毒肝炎初治患者接受干扰素联合恩替卡韦治疗效果确切,可显著改善肝功能,且安全性高,值得推广。
Objective To investigate the clinical effect of interferon combined with entecavir in the treatment of patients with chronic hepatitis B. Methods From June 2014 to January 2016, 76 cases of patients with chronic hepatitis B in our hospital treated first time were selected as the research objects and randomly divided into observation group and control group, with 38 cases in each group. The control group was given interferon treatment, and the observation group added entecavir based on the control group. The virological and serological indexes, liver function index and the incidence of adverse reactions were observed in the two groups. Results After 8 weeks of treatment, the differences of HBV DNA negative rate, HBeAg negative rate and HBeAg serum conversion rate in the two groups had no statistical significance （P〉0.05）; after 24 weeks of treatment, the above indexes in the observation group were significantly higher than those in the control group （P〈0.05）; after 48 weeks of treatment, the above indexes in the observation group were significantly higher than those in the control group （P〈0.05）. There was no significant difference of serum AST and ALT levels between the two groups before treatment （P〉0.05）; after 48 weeks of treatment, the serum AST and ALT levels in the two groups decreased （P〈0.05）, and the observation group were significantly lower than those in the control group, the differences were statistically significant （P〈0.05）. There was no significant difference of incidence of adverse reactions between the two groups （P〉0.05）. Conclusion Interferon combined with enteeavir in the treatment of patients with chronic hepatitis B has exact treatment effect, which can significantly improve liver function with high safety, it is worth promoting.
出处
《临床医学研究与实践》
2017年第15期37-38,40,共3页
Clinical Research and Practice
